



**(301) 366-4841**

**(Issuer Telephone number)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

On February 11, 2014, a representative of Neuralstem, Inc. (the “Company”) presented at the BIO CEO & Investor Conference 2014. The conference was held at the Waldorf Astoria Hotel in New York, NY. Filed herewith as Exhibit 99.01 are the slides that were presented at such conference. The slides are also available on the Company’s website at [www.neuralstem.com](http://www.neuralstem.com).

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit Number** Description

99.01 Slides presented at conference on February 11, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 11, 2014 Neuralstem, Inc.

/s/ Richard Garr  
By: Richard Garr  
Chief Executive Officer



INDEX TO EXHIBITS

**Exhibit Number** Description

99.01 Slides presented at conference on February 11, 2014